<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Prostate cancer in older males
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Prostate cancer in older males
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Prostate cancer in older males
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan L Wright, MD, MS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul H Lange, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerome P Richie, MD, FACS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            W Robert Lee, MD, MS, MEd
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 19, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H695146355">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prostate cancer in older males is particularly important because of the high incidence and prevalence of disease and mortality in this group of patients. Management of prostate cancer in males over the age of 70 can be complicated by the comorbidity, competing mortality, and health status issues specific to this group; in addition, there are generally limited data on the efficacy of newer treatments because older patients are underrepresented in clinical trials in prostate cancer.
        </p>
        <p>
         The initial treatment for older males with competing morbidity and mortality who have localized prostate cancer or advanced disease will be reviewed here. The approach to these issues in younger patients is reviewed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6940.html" rel="external">
          "Initial approach to low- and very low-risk clinically localized prostate cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6947.html" rel="external">
          "Initial management of regionally localized intermediate-, high-, and very high-risk prostate cancer and those with clinical lymph node involvement"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6941.html" rel="external">
          "Overview of systemic treatment for recurrent or metastatic castration-sensitive prostate cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">
          "Overview of the treatment of castration-resistant prostate cancer (CRPC)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3843022924">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The public health burden of treating older males with both early and advanced prostate cancer is substantial and is expected to increase over the coming decades:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The incidence of prostate cancer is strongly correlated with age and disproportionately affects older adults. Prostate cancer incidence rates rapidly rise with increasing age starting around age 50 years, with the highest rates seen in those aged 70 to 80 years  (
         <a class="graphic graphic_figure graphicRef50706" href="/z/d/graphic/50706.html" rel="external">
          figure 1
         </a>
         ). Thus, the estimated prevalence for males aged 75 years or greater is over one million males [
         <a href="#rid1">
          1
         </a>
         ]. In the United States in 2018, 58 percent of new cases were diagnosed in males 65 years of age or older [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prostate cancer is the third most common cause of cancer death among males aged 80 years and older [
         <a href="#rid3">
          3
         </a>
         ]. Although the case-fatality rate of prostate cancer is quite low, deaths occur disproportionately in older males, owing to the long natural history of the disease. Thus, 41 percent of males who die of prostate cancer are between age 75 and 84 years, and 30 percent are 85 years or older.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The median age at prostate cancer diagnosis is 66, but the median age of males who develop metastatic disease is considerably older, and the median age of those who die from the disease is 80 [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Given the aging population, it is estimated that the total number of patients with prostate cancer aged 70 and older will increase between 2018 and 2030 from 585,000 to 778,000 in the United States [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13013302">
         <span class="h1">
          PATIENT CLASSIFICATION BASED ON HEALTH STATUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Geriatric patients often have less functional independence, a greater number of medical comorbidities and associated medications, a decline in cognitive and nutritional status, and/or a lack of social support [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2823.html" rel="external">
          "Systemic chemotherapy for cancer in older adults", section on 'Challenges specific to older-adult patients'
         </a>
         .)
        </p>
        <p>
         As a result, treatment decisions for both early and advanced-stage prostate cancer must take into account the risk of dying from prostate cancer (tumor grade and stage), as well as the risk of dying from another cause (ie, comorbidities, overall health status), the risks of treatment, and patient preferences. These issues have been integrated into recommendations for the management of older males with prostate cancer in the consensus-based guidelines of the International Society of Geriatric Oncology (SIOG), which have been updated several times, most recently in 2019 [
         <a href="#rid6">
          6-8
         </a>
         ]. The 2019 guidelines were fully endorsed by the European Association of Urology (EAU) and the European Society for Radiotherapy and Oncology (ESTRO), and the recommendations are now referred to as the EAU/ESTRO/SIOG guidelines [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         The most recent recommendations emphasize that treatment decisions should be based on health status rather than age [
         <a href="#rid8">
          8
         </a>
         ]. The recommendations include several standardized assessments of health status, which can be easily and quickly administered in the clinical setting  (
         <a class="graphic graphic_table graphicRef121919" href="/z/d/graphic/121919.html" rel="external">
          table 1
         </a>
         ). These include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An initial assessment of health status using the Geriatric 8 (G8) screening instrument [
         <a href="#rid9">
          9
         </a>
         ]. This assessment incorporates eight different parameters, including food intake, weight change over the last three months, mobility, neuropsychological issues, body mass index, use of three or more medications per day, the patient's self-assessment of his health status, and age. Individual scores are provided for specific answers, and based on the total score, patients were divided into those deemed "fit" (score 14 or lower out of 17) and those considered to have significant impairment (score &gt;14), who therefore, might benefit from a comprehensive geriatric assessment (CGA).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening for cognitive impairment using the Mini-Cog test is also recommended [
         <a href="#rid10">
          10
         </a>
         ]. The Mini-Cog test consists of a three-word recall (with 1 point for each correct word) and a clock-drawing test (with 2 points for a correctly drawn clock and 0 points for an abnormal clock) that can be completed in five minutes. A cutoff point of ≤3 out of 5 points indicates a need for a full evaluation for dementia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with impairment on the G8 health assessment (ie, a score of ≤14 out of 17), the second step is a CGA [
         <a href="#rid6">
          6
         </a>
         ]. There is no uniform CGA measurement tool. American Society of Clinical Oncology (ASCO) guidelines provide a minimum dataset for practical assessment of vulnerabilities in older patients with cancer  (
         <a class="graphic graphic_table graphicRef118720" href="/z/d/graphic/118720.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid11">
          11
         </a>
         ]. The guidelines also include recommendations for specific interventions guided by the geriatric assessment  (
         <a class="graphic graphic_table graphicRef118298" href="/z/d/graphic/118298.html" rel="external">
          table 3
         </a>
         ). A CGA is also recommended by the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for Older Adult Oncology [
         <a href="#rid12">
          12
         </a>
         ]. The practical aspects of conducting a CGA are addressed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2808.html" rel="external">
          "Comprehensive geriatric assessment for patients with cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         At minimum, the following domains should be assessed:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Comorbidity
         </strong>
         – An evaluation of an individual's comorbidities (ie, Cumulative Illness Rating Score for Geriatrics [CIRS-G]) is used to determine whether the impairment is reversible or irreversible. The CIRS-G rates comorbid conditions on a 0 to 4 scale:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Grade 0
         </strong>
         – No problem
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Grade 1
         </strong>
         – Current mild problem or past significant problem
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Grade 2
         </strong>
         – Moderate disability or morbidity; requires first-line therapy
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Grade 3
         </strong>
         – Severe/constant significant disability; uncontrollable chronic problem
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Grade 4
         </strong>
         – Extremely severe; immediate treatment required; end-organ failure; severe impairment in function
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dependence
         </strong>
         – Dependence includes an assessment of activities of daily living (ADLs), which address home independence, as well as instrumental activities of daily living (IADLs), which assess independence in the community setting  (
         <a class="graphic graphic_table graphicRef63647" href="/z/d/graphic/63647.html" rel="external">
          table 4
         </a>
         ). The IADL scale can be modified further; the SIOG recognizes that all eight categories of the IADL scale may not be appropriate for a male population and thus allows for only four items to be used in the screening [
         <a href="#rid13">
          13
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Financial management
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Medication management
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Use of transportation
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Use of the telephone
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nutritional status
         </strong>
         – An individual's nutritional status can be estimated by determining weight loss over the preceding three months:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Good nutritional status
         </strong>
         – Weight loss &lt;5 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Risk of malnutrition
         </strong>
         – Weight loss 5 to 10 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Severe malnutrition
         </strong>
         – Weight loss &gt;10 percent
        </p>
        <p>
        </p>
        <p>
         The CGA needs to be followed by specific interventions, implemented in response to any vulnerabilities that are identified  (
         <a class="graphic graphic_table graphicRef118298" href="/z/d/graphic/118298.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid14">
          14
         </a>
         ]. Based on this information, a patient can be categorized into one of three groups:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fit/healthy
         </strong>
         – Defined as having a G8 score &gt;14 out of 17, no comorbidities, no dependence, no malnutrition, and no cognitive impairment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vulnerable
         </strong>
         – Patients have either some impairment in ADLs, moderate malnutrition, or moderate comorbidities. Following appropriate geriatric intervention, these patients should receive standard treatment for their prostate cancer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Frail
         </strong>
         – Older patients who either are dependent on multiple ADLs or have severe malnutrition or severe comorbidities. Although geriatric intervention may be beneficial for some patients, treatment must generally be adjusted to take into account the patient's impairment.
        </p>
        <p>
        </p>
        <p>
         A decision-tree approach to assessing health status in older males with prostate cancer to inform treatment decisions is presented in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef121917" href="/z/d/graphic/121917.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         The NCCN consensus-based guidelines for Older Adult Oncology support the use of a CGA, with similar recommendations that state health rather than age should be the determinant of treatment option in older males with prostate cancer [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1272128656">
         <span class="h2">
          Predicting life expectancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A related issue, both for issues of screening and management of patients in whom prostate cancer has been diagnosed, is that clinicians have only limited ability to predict life expectancy in males with localized prostate cancer [
         <a href="#rid15">
          15,16
         </a>
         ]. Because life tables do not consider factors other than an individual's chronologic age, they do not accurately predict survival in males with multiple comorbidities. In a study of males with prostate cancer, life expectancy tables overestimated survival by 32 percent in those males with a Charlson Comorbidity Index ≥3  (
         <a class="graphic graphic_table graphicRef72047" href="/z/d/graphic/72047.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. Nomograms are available to predict 10-year life expectancy in males with localized prostate cancer that may be more accurate than life tables because they take into account comorbidities [
         <a href="#rid18">
          18
         </a>
         ]. However, updated guidelines from the EAU/ESTRO/SIOG recommend the use of
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Feprognosis.ucsf.edu%2F&amp;token=io%2FPsaQQZxDpnBUAopDlbxmWcXPlSVI1bLzDm8ooai7%2F%2FzOcgvJJo5AsD%2B9BSbts&amp;TOPIC_ID=14257" target="_blank">
          ePrognosis
         </a>
         in the setting of localized prostate cancer to estimate non-cancer-specific life expectancy and aid in decision making [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2206.html" rel="external">
          "Survival estimates in advanced terminal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H695146363">
         <span class="h1">
          PROSTATE CANCER SCREENING
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of prostate cancer screening is controversial, both in older and in younger males. The issues and screening guidelines are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7567.html" rel="external">
          "Screening for prostate cancer", section on 'Discontinuing screening'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3525346307">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2571755390">
         <span class="h2">
          Risk assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial management plan for males with newly diagnosed prostate cancer depends on a pretreatment assessment of the risk of locoregional recurrence or disseminated disease combined with patient age, life expectancy, overall medical condition (including performance status and comorbidities), presence or absence of symptoms, and patient preferences to make decisions about the optimal treatment for an individual patient. Key factors in this assessment include clinical staging of the extent of disease  (
         <a class="graphic graphic_table graphicRef110728" href="/z/d/graphic/110728.html" rel="external">
          table 6
         </a>
         and
         <a class="graphic graphic_table graphicRef110729" href="/z/d/graphic/110729.html" rel="external">
          table 7
         </a>
         ), the pretreatment serum prostate-specific antigen (PSA), the Gleason score in the pretreatment biopsy, and in some cases, the results of pretreatment imaging studies. (See
         <a class="medical medical_review" href="/z/d/html/6943.html" rel="external">
          "Localized prostate cancer: Risk stratification and choice of initial treatment", section on 'Risk stratification'
         </a>
         .)
        </p>
        <p>
         Based on this information and the results of additional studies as may be indicated, patients are divided into several categories, which provide the basis for treatment decisions  (
         <a class="graphic graphic_table graphicRef118962" href="/z/d/graphic/118962.html" rel="external">
          table 8
         </a>
         ). These categories were based on the D'Amico classification [
         <a href="#rid19">
          19
         </a>
         ], which is still used in the consensus-based treatment recommendations of the European Association of Urology (EAU)/European Society for Radiotherapy and Oncology (ESTRO)/International Society of Geriatric Oncology (SIOG) [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6943.html" rel="external">
          "Localized prostate cancer: Risk stratification and choice of initial treatment", section on 'Risk stratification'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H695146370">
         <span class="h2">
          Localized disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         As is the case for younger males, potentially curative treatment options for the older man with localized prostate cancer include radiation therapy (RT; both external beam and brachytherapy) and radical prostatectomy. Other standard options include active surveillance (ie, careful monitoring with PSA, rectal examinations, and periodic biopsies, with potentially curative treatment on progression) or watch and wait (observation until the patient becomes symptomatically progressive, then treatment is instituted). Androgen deprivation therapy (ADT) has also been used [
         <a href="#rid20">
          20,21
         </a>
         ], although it is discouraged as primary therapy in males with lower risk disease, owing to an increase in all-cause mortality. Its use is also discouraged in males with unfavorable-risk disease because of concerns about undertreatment [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6940.html" rel="external">
          "Initial approach to low- and very low-risk clinically localized prostate cancer", section on 'Androgen deprivation therapy alone'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6947.html" rel="external">
          "Initial management of regionally localized intermediate-, high-, and very high-risk prostate cancer and those with clinical lymph node involvement", section on 'Benefits of definitive treatment'
         </a>
         .)
        </p>
        <p>
         Several publications have reported on the treatment options that are actually used for older males [
         <a href="#rid20">
          20,22-25
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) indicate that, for males over the age of 75 years, the use of ADT is declining among males with low-risk disease [
         <a href="#rid25">
          25
         </a>
         ]. For those with low-risk disease, the proportion undergoing surveillance was 76 percent, and primary ADT declined from approximately 30 percent in 2000 to 2004 to &lt;5 percent. On the other hand, for those with high-risk disease over the age of 75 years in the CaPSURE database, primary ADT remained the most common treatment, utilized in 67 percent of males.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Yang et al used the National Cancer Database (NCDB) to examine definitive therapy (prostatectomy or RT) among 400,000 males diagnosed with intermediate- or high-risk prostate cancer between 2004 and 2012 [
         <a href="#rid20">
          20
         </a>
         ]. With increasing age and comorbidity, patients were less likely to receive definitive treatment, and more than 40 percent of males over the age of 80 did not receive definitive treatment with surgery or RT. Compared with males who received definitive treatment, those who did not receive definitive therapy were more likely to die within one year of diagnosis, regardless of age or prostate cancer disease risk, suggesting that decision making was reasonably aligned with estimated life expectancy [
         <a href="#rid21">
          21
         </a>
         ]. However, over one-half of those males with high-risk disease who did not receive definitive therapy went on to receive ADT instead. Given that the benefits of ADT are associated primarily with advanced rather than localized disease [
         <a href="#rid26">
          26-28
         </a>
         ], that primary ADT for localized prostate cancer is associated with decreased overall survival and notable side effects (metabolic syndrome, fractures, and cognitive, cardiovascular, and sexual dysfunction), and that safer, more effective treatment approaches exist (eg, RT), the authors concluded that definitive therapy was underused and ADT was widely overused in this population.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H258749388">
         <span class="h3">
          Life expectancy and impact of disease on survival
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment decisions for males who present with localized prostate cancer need to consider both the life expectancy of the patient independent of his prostate cancer and the natural history of the prostate cancer. Data on the natural history of untreated prostate cancer indicate that, although there are more deaths due to competing risks in males over the age of 70 years, especially in those with lower grade disease, a significant number of males over the age of 70 at diagnosis will eventually die of prostate cancer. The decision of whether or not to proceed with aggressive therapy for localized disease thus should incorporate not only the patient's age, but also the presence or absence of significant comorbidity, as well as the aggressiveness of the prostate cancer, as estimated by risk stratification.
        </p>
        <p>
         Two large studies illustrate the relationships between age, comorbidity, and the natural history of prostate cancer:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database analyzed the risk of prostate cancer-specific mortality in 31,137 males ≥65 years old diagnosed with T1 to T2 disease between 1992 and 2009 [
         <a href="#rid29">
          29
         </a>
         ]. All males were initially managed conservatively, without either definitive therapy (surgery, RT, cryotherapy) or ADT within six months of the original diagnosis. For males with Gleason 5 to 7 disease, the 15-year prostate cancer-specific mortality rates for males aged 65 to 74 and those ≥75 years were 5.7 and 10 percent, respectively. For those with Gleason 8 to 10 disease, the 15-year prostate cancer-specific mortality rates were 22 and 27 percent, respectively. However, 24 and 38 percent of males, respectively, ultimately received ADT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study from the SEER database analyzed outcomes in 3183 males who were included in the Prostate Cancer Outcomes Study (PCOS) [
         <a href="#rid30">
          30
         </a>
         ]. These males were diagnosed with localized disease between 1994 and 1995 and were followed for 14 years. Subjects were assessed for the presence of 12 major comorbidities at presentation  (
         <a class="graphic graphic_table graphicRef89481" href="/z/d/graphic/89481.html" rel="external">
          table 9
         </a>
         ). Outcomes were assessed as a function of age (≤55, 56 to 65, 66 to 75, or ≥76 years), number of comorbidities at presentation (0, 1, 2, or ≥3), tumor risk category (low, intermediate, or high), and treatment (aggressive [surgery, RT] versus nonaggressive [ADT] alone, watchful waiting).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         At a follow-up of 14 years, the cumulative mortality rates from all causes other than prostate cancer were 24, 33, 46, and 57 percent for males with 0, 1, 2, or ≥3 comorbidities. By contrast, the rates of prostate cancer mortality at this same time point were 3, 7, and 18 percent for males with low-, intermediate-, and high-risk disease  (
         <a class="graphic graphic_figure graphicRef89482" href="/z/d/graphic/89482.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The risk of prostate cancer mortality was further analyzed based on whether patients were initially managed with aggressive treatment (surgery, RT) or other approaches (watchful waiting, ADT). Males with no comorbidities or only one comorbidity treated with ADT or watchful waiting had a statistically significant increase in risk of prostate cancer mortality compared with those treated aggressively (hazard ratios [HRs] 2.4 and 2.2, respectively). The risks for those with two or three comorbidities managed conservatively were not statistically significant (HRs 1.6 and 1.5, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As noted above, year 2019 consensus-based guidelines from the EAU/ESTRO/SIOG recommend the use of
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Feprognosis.ucsf.edu%2F&amp;token=io%2FPsaQQZxDpnBUAopDlbxmWcXPlSVI1bLzDm8ooai7%2F%2FzOcgvJJo5AsD%2B9BSbts&amp;TOPIC_ID=14257" target="_blank">
          ePrognosis
         </a>
         in the setting of localized prostate cancer to estimate non-cancer-specific life expectancy and aid in decision making [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="local">
          'Predicting life expectancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H807361121">
         <span class="h3">
          Active surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with very low- and low-risk disease are less likely to derive benefit from immediate intervention than are patients with higher risk disease. (See
         <a class="medical medical_review" href="/z/d/html/6943.html" rel="external">
          "Localized prostate cancer: Risk stratification and choice of initial treatment", section on 'Clinically localized, NCCN very low risk'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6943.html" rel="external">
          "Localized prostate cancer: Risk stratification and choice of initial treatment", section on 'Clinically localized, NCCN low risk'
         </a>
         .)
        </p>
        <p>
         An approach of careful monitoring, with delayed definitive intervention if there is evidence of progression, is an appropriate option for many patients with very low- and low-risk disease and for some males with favorable intermediate-risk disease. (See
         <a class="medical medical_review" href="/z/d/html/6943.html" rel="external">
          "Localized prostate cancer: Risk stratification and choice of initial treatment", section on 'Clinically localized, NCCN intermediate risk'
         </a>
         .)
        </p>
        <p>
         The criteria for patient selection for active surveillance and the components of monitoring for disease progression during active surveillance are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6922.html" rel="external">
          "Active surveillance for males with clinically localized prostate cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H322087631">
         <span class="h4">
          Versus watchful waiting
         </span>
         <span class="headingEndMark">
          —
         </span>
         Active surveillance must be distinguished from "watchful waiting," which is based on the premise that some males will not benefit from definitive treatment of their localized prostate cancer. For patients managed with watchful waiting, the decision is made at the outset that the patient is not a candidate for definitive therapy and to provide palliative treatment (typically ADT) or transurethral resection of the prostate for urinary obstruction if and when symptomatic progression requires therapy. Watchful waiting may be an acceptable alternative for males with a short life expectancy based on age and/or substantial comorbidity.
        </p>
        <p class="headingAnchor" id="H4031667760">
         <span class="h3">
          Definitive local therapy
         </span>
        </p>
        <p class="headingAnchor" id="H695146377">
         <span class="h4">
          Radical prostatectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radical prostatectomy may be an appropriate option for males with low-, intermediate-, or high-risk prostate cancer. (See
         <a class="medical medical_review" href="/z/d/html/6944.html" rel="external">
          "Radical prostatectomy for localized prostate cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13014038">
         <span class="h5">
          Efficacy in older males
         </span>
         <span class="headingEndMark">
          —
         </span>
         Assessing the effectiveness of radical prostatectomy in older males with localized prostate cancer is difficult.
        </p>
        <p>
         Although one randomized trial found that radical prostatectomy in males with localized prostate cancer improved disease-specific survival compared with watchful waiting, the study excluded males over age 75 years [
         <a href="#rid31">
          31,32
         </a>
         ]. In the latest analysis, radical prostatectomy significantly improved cancer-specific survival and reduced the risk of distant metastases, both in males under the age of 65 and in those 65 and older [
         <a href="#rid32">
          32
         </a>
         ]. However, among males 65 years of age or older at diagnosis, the between-group differences were smaller for all investigated endpoints. (See
         <a class="medical medical_review" href="/z/d/html/6944.html" rel="external">
          "Radical prostatectomy for localized prostate cancer", section on 'Survival impact of radical prostatectomy'
         </a>
         .)
        </p>
        <p>
         Observational data do support a role for radical prostatectomy in selected patients [
         <a href="#rid33">
          33-39
         </a>
         ]. As an example, in a study of 4500 males undergoing surgery, 17 percent of whom were older than 70 years, higher grade and higher stage disease was seen in those aged 70 or greater compared with younger cohorts [
         <a href="#rid34">
          34
         </a>
         ]. Although unadjusted disease-specific survival was worse in those aged ≥70 years, age was not a significant predictor of survival on multivariate analysis that incorporated stage and grade. This is similar to other series that found worse pathologic characteristics at radical prostatectomy in older patients [
         <a href="#rid35">
          35,36
         </a>
         ] but similar or better disease-specific survival compared with younger cohorts [
         <a href="#rid35">
          35-37
         </a>
         ]. In another series of 386 males over the age of 70 years, the 15-year prostate cancer-specific and overall survival rates were 90 and 69 percent, respectively [
         <a href="#rid38">
          38
         </a>
         ]. This is better than in a population-based cohort of males over the age of 70, in which the 10-year overall survival rate for males undergoing radical prostatectomy was 59 percent [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         A predictive model that included an individual's comorbidities was developed to improve the accuracy of predicting overall mortality in males with prostate cancer undergoing surgery [
         <a href="#rid40">
          40
         </a>
         ]. This model incorporates Gleason grade, serum PSA, and Charlson Comorbidity Index  (
         <a class="graphic graphic_table graphicRef72047" href="/z/d/graphic/72047.html" rel="external">
          table 5
         </a>
         ) to illustrate the impact of the degree of comorbidity on overall survival in males over the age of 70 years who undergo radical prostatectomy  (
         <a class="graphic graphic_table graphicRef74222" href="/z/d/graphic/74222.html" rel="external">
          table 10
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H695146384">
         <span class="h5">
          Side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         One of the biggest concerns with radical prostatectomy in older males is the higher rate of complications compared with younger patients, particularly related to urinary and sexual function. As an example, in one large series, the rate of complications increased progressively with age (4, 7, 9, and 14 percent for ages 40 to 49, 50 to 59, 60 to 69, and ≥70 years, respectively) [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6944.html" rel="external">
          "Radical prostatectomy for localized prostate cancer", section on 'Functional outcomes'
         </a>
         .)
        </p>
        <p>
         Several studies have reported higher rates of urinary and sexual dysfunction in older males. In a population-based study, frequent urinary leakage was significantly less common at two years postoperation in males &lt;74 years of age compared with those 75 to 79 years (5 to 10 versus 27 percent, p = 0.03) [
         <a href="#rid42">
          42
         </a>
         ]. Similarly, potency rates were lower in males 75 to 79 years compared with those under age 60 years (19 versus 39 percent). This population-based study also collected data on males treated conservatively. Compared with those treated surgically or with RT, those treated conservatively had fewer urinary and bowel issues at two years [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Older males may require secondary interventions more frequently following radical prostatectomy [
         <a href="#rid44">
          44
         </a>
         ]. Compared with young males (age &lt;50 years), a higher proportion of males over the age of 70 years required treatment for anastomotic strictures (10.8 versus 5.8 percent) or placement of artificial urinary sphincters (2.5 versus 0.5 percent). Data from CaPSURE show that males over the age of 65 are less likely to return to potency, continence, and physical health one year after radical prostatectomy [
         <a href="#rid45">
          45
         </a>
         ]. Although single-institution series report higher overall continence and potency rates compared with multi-institution databases, such reports still suggest lower rates in older as compared with younger males [
         <a href="#rid41">
          41,46,47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H695146391">
         <span class="h4">
          Radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         RT may be an appropriate option for males with low-, intermediate-, high-, or very high-risk disease. (See
         <a class="medical medical_review" href="/z/d/html/6946.html" rel="external">
          "External beam radiation therapy for localized prostate cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6923.html" rel="external">
          "Brachytherapy for low-risk or favorable intermediate-risk, clinically localized prostate cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13014072">
         <span class="h5">
          Disease control in older males
         </span>
         <span class="headingEndMark">
          —
         </span>
         RT is used more commonly than radical prostatectomy for treatment of older males with localized prostate cancer [
         <a href="#rid23">
          23,48,49
         </a>
         ].
        </p>
        <p>
         In one study of 381 males aged 75 years or older, external beam RT was associated with worse prostate cancer-specific survival in males with high-risk disease [
         <a href="#rid50">
          50
         </a>
         ]. Another study of 2474 males with localized disease receiving either brachytherapy alone or brachytherapy with neoadjuvant ADT found increased overall mortality in older males (≥73 years, n = 1268) receiving combined treatment (adjusted HR 1.24, 95% CI 1.01-1.53) [
         <a href="#rid51">
          51
         </a>
         ]. This increased overall mortality was not seen in males younger than 73 years of age (p = 0.34). In this study, only 12 percent of males had high-risk disease, and prostate cancer-specific survival was not reported. Other studies have not found advanced age to be associated with biochemical recurrence after RT [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p>
         The effect of comorbidity, rather than age, on survival has been studied following RT for prostate cancer. A randomized study of external beam RT with or without six months of ADT found that the survival advantage for intermediate- and high-risk patients was only seen in those with minimal or no medical comorbidity [
         <a href="#rid54">
          54-56
         </a>
         ]. At a median follow-up of 16.6 years, RT plus ADT was associated with better overall survival than RT alone for the 157 males with no or minimal comorbidity (15-year survival rate 43.8 versus 30.5 percent, p = 0.04). By contrast, for the 49 males with moderate or severe comorbidity, RT plus ADT was associated with worse overall survival (15-year survival rate 8.3 versus 20.0 percent, p = 0.07). In a separate study of 1978 males with intermediate-risk disease aged 66 to 75 years (median 71 years) undergoing RT, the role of cardiovascular disease in survival outcomes was explored [
         <a href="#rid57">
          57
         </a>
         ]. Males with cardiovascular disease had a reduction in the risk of prostate cancer-specific mortality (HR 0.20, 95% CI 0.04-0.99), perhaps due to competing risks for mortality.
        </p>
        <p>
         In contrast to these studies of males with comorbidities, analyses of healthy males have suggested that aggressive RT is beneficial for older males with high-risk disease. In a retrospective study of 764 healthy older males (age ≥65 years) with high-risk disease, brachytherapy alone was compared with brachytherapy combined with external beam RT and four months of ADT [
         <a href="#rid58">
          58
         </a>
         ]. Healthy was defined as no history of diabetes, congestive heart failure and coronary artery disease, or corrected (surgically or stented) coronary artery disease. At a median follow-up of 4.9 years, those receiving combined treatment had a 70 percent reduction in prostate cancer-specific mortality compared with those receiving brachytherapy only (HR 0.29, 95% CI 0.12-0.68). In another study of 5077 males treated with RT, neoadjuvant ADT was not associated with an increased risk of overall mortality in males with few or no comorbidities [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         Two large randomized trials in patients with locally advanced prostate cancer demonstrated that RT plus ADT significantly decreases mortality due to prostate cancer and prolongs overall survival, although older males were underrepresented in these trials [
         <a href="#rid60">
          60-62
         </a>
         ]. A study from the SEER-Medicare database analyzed cohorts of 8694 older males (age 76 to 85 years) with T2 or T3 disease and 2260 screen-detected males (age 65 to 85 years) with high-risk T1c disease  (
         <a class="graphic graphic_table graphicRef110728" href="/z/d/graphic/110728.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid63">
          63
         </a>
         ]. Although limited by the observational source of the data, these analyses demonstrated a significant improvement in overall and disease-specific survival for RT plus ADT compared with ADT alone; the magnitude of benefit was similar to that in the randomized trials after propensity matching for comorbidity and other risk factors. (See
         <a class="medical medical_review" href="/z/d/html/6947.html" rel="external">
          "Initial management of regionally localized intermediate-, high-, and very high-risk prostate cancer and those with clinical lymph node involvement", section on 'Benefits of definitive treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13014089">
         <span class="h5">
          Side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies are conflicting as to whether or not age is an independent predictor of genitourinary and gastrointestinal side effects after RT. Some articles have found similar side effect profiles for older males undergoing RT compared with their younger counterparts [
         <a href="#rid64">
          64-66
         </a>
         ], whereas others have found advanced age to be predictive of increased local side effects [
         <a href="#rid67">
          67-69
         </a>
         ]. Studies have also suggested that males over the age of 70 develop toxicities more quickly [
         <a href="#rid67">
          67
         </a>
         ]. Studies on brachytherapy have found that comorbid conditions are an important predictor of complications, along with age [
         <a href="#rid70">
          70,71
         </a>
         ]. In an analysis of the SEER-Medicare database, a higher Charlson Comorbidity Index  (
         <a class="graphic graphic_table graphicRef72047" href="/z/d/graphic/72047.html" rel="external">
          table 5
         </a>
         ) and advanced age were both associated with increased urinary and bowel complications [
         <a href="#rid70">
          70
         </a>
         ]. Another study of 528 males undergoing RT found functional outcomes to be affected by both age and comorbidity, especially diabetes [
         <a href="#rid71">
          71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6946.html" rel="external">
          "External beam radiation therapy for localized prostate cancer", section on 'Complications'
         </a>
         .)
        </p>
        <p>
         The use of ADT in combination with external beam RT has become the standard of care for males receiving RT for high- and intermediate-risk prostate cancer, based on improvements in cancer-specific and overall survival observed in multiple randomized trials. The optimal duration and timing (ie, starting before RT versus concurrently) are controversial areas. However, the role of ADT in combination with RT in older males needs to be carefully considered due to the higher rate of adverse events in this population. (See
         <a class="medical medical_review" href="/z/d/html/6947.html" rel="external">
          "Initial management of regionally localized intermediate-, high-, and very high-risk prostate cancer and those with clinical lymph node involvement", section on 'Role of concurrent ADT'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6927.html" rel="external">
          "Side effects of androgen deprivation therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3716521535">
         <span class="h4">
          Post-treatment surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mainstay of post-treatment surveillance after definitive local therapy for prostate cancer is periodic assessment of serum PSA. Post-treatment surveillance for males who have received definitive local treatment for prostate cancer is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6928.html" rel="external">
          "Follow-up surveillance after definitive local treatment for prostate cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H695146405">
         <span class="h3">
          Androgen deprivation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         ADT alone has been used commonly as a primary treatment in older males, rather than definitive surgery or RT [
         <a href="#rid20">
          20,23,26,48
         </a>
         ]. However, increasing data have raised concerns about this practice, and the use of ADT has declined [
         <a href="#rid26">
          26
         </a>
         ]. These concerns are based on multiple studies suggesting increased mortality and shorter survival in patients given ADT as primary treatment; these studies are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6940.html" rel="external">
          "Initial approach to low- and very low-risk clinically localized prostate cancer", section on 'Androgen deprivation therapy alone'
         </a>
         .)
        </p>
        <p>
         The American Urological Association (AUA) guidelines recommend that primary ADT not be included among the standard treatment options for males with localized prostate cancer unless for palliation of local symptoms in select patients with a limited life expectancy for whom definitive local therapy is not advised [
         <a href="#rid72">
          72
         </a>
         ]. National Comprehensive Cancer Network (NCCN) guidelines also do not endorse primary ADT as a treatment option for males with clinically localized disease [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3914413331">
         <span class="h3">
          Guidelines from expert groups
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most extensive consensus-based recommendations for managing localized prostate cancer in older males are those of the SIOG, which have been updated several times [
         <a href="#rid6">
          6-8
         </a>
         ]. The most recent version, which has been endorsed by the EAU and ESTRO [
         <a href="#rid8">
          8
         </a>
         ], emphasizes a stepwise approach to the initial assessment of health status and life expectancy and also emphasizes early introduction of palliative care. (See
         <a class="local">
          'Patient classification based on health status'
         </a>
         above.)
        </p>
        <p>
         Specific consensus-based recommendations for managing older males with localized prostate cancer from the EAU/ESTRO/SIOG are outlined in the table  (
         <a class="graphic graphic_table graphicRef121918" href="/z/d/graphic/121918.html" rel="external">
          table 11
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H695146339">
         <span class="h2">
          Advanced prostate cancer
         </span>
        </p>
        <p class="headingAnchor" id="H3363314636">
         <span class="h3">
          Supportive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Guidelines from both the EAU/ESTRO/SIOG and the American Society of Clinical Oncology (ASCO) emphasize the importance of early referral to palliative care, particularly for individuals with advanced cancer [
         <a href="#rid8">
          8,74
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14240.html" rel="external">
          "Benefits, services, and models of subspecialty palliative care"
         </a>
         .)
        </p>
        <p>
         For males with bone-metastatic castration-resistant prostate cancer (CRPC), osteoclast inhibition (with
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         or a bisphosphonate) significantly decreases the rate of skeletal-related complications. These agents are not indicated in males with metastatic castration-sensitive prostate cancer given the lack of benefit in trials conducted in this setting. (See
         <a class="medical medical_review" href="/z/d/html/17128.html" rel="external">
          "Bone metastases in advanced prostate cancer: Management", section on 'Castration-resistant disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H258747715">
         <span class="h3">
          Castration-sensitive prostate cancer
         </span>
        </p>
        <p class="headingAnchor" id="H2987419508">
         <span class="h4">
          ADT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial management of older males with newly diagnosed advanced prostate cancer is generally androgen deprivation therapy (ADT). (See
         <a class="medical medical_review" href="/z/d/html/6951.html" rel="external">
          "Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer"
         </a>
         .)
        </p>
        <p>
         The side effects of ADT are of particular concern in older males. (See
         <a class="medical medical_review" href="/z/d/html/6927.html" rel="external">
          "Side effects of androgen deprivation therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ADT is associated with an increased risk of fractures [
         <a href="#rid75">
          75,76
         </a>
         ], and these males have a higher likelihood of being osteopenic [
         <a href="#rid77">
          77
         </a>
         ]. Males 70 years of age and older appear to be at greater risk of having decreased lean body mass compared with younger males treated with ADT [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endocrine changes occur with ADT, including a higher risk of developing metabolic syndrome and diabetes [
         <a href="#rid79">
          79-83
         </a>
         ]. The prevalence of metabolic syndrome increases with age [
         <a href="#rid84">
          84
         </a>
         ], indicating that older males started on ADT may either have or be at risk of developing or worsening aspects of metabolic syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Males treated with ADT may be at a higher risk of developing coronary artery disease and all-cause mortality [
         <a href="#rid85">
          85,86
         </a>
         ]. The relationship between coronary artery disease and treatment with ADT is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6927.html" rel="external">
          "Side effects of androgen deprivation therapy", section on 'Potential cardiovascular harm'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depressive, cognitive, and constitutional disorders occur more commonly in males receiving ADT [
         <a href="#rid87">
          87,88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sarcopenia and frailty are of general concern in older adults, and they may be exacerbated by ADT.
        </p>
        <p>
        </p>
        <p>
         Although ADT is an important treatment for prostate cancer, the potential complications of such therapy and the interaction with existing comorbidities need to be considered on an individualized basis. In some cases that are associated with a slow natural history and low disease burden, surveillance alone may be indicated. (See
         <a class="medical medical_review" href="/z/d/html/6927.html" rel="external">
          "Side effects of androgen deprivation therapy"
         </a>
         .)
        </p>
        <p>
         If ADT is chosen, consideration may be given to intermittent androgen deprivation (IAD), rather than continuous ADT, in older males in an attempt to decrease the side effect profile. However, the long-term impact of IAD on survival, the optimal timing, the triggers for initiation of additional treatment, and the populations that are candidates for IAD have not been defined. Furthermore, recovery of serum testosterone levels in males on ADT may be prolonged in older males. An expert panel from ASCO has concluded that the data are insufficient to support the use of IAD outside of a clinical trial [
         <a href="#rid89">
          89,90
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6951.html" rel="external">
          "Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer", section on 'Intermittent versus continuous ADT'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1468462529">
         <span class="h4">
          ADT plus systemic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         ADT has been successfully combined with both
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         and
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         in males with newly diagnosed, very high-risk, non-metastatic, hormone-sensitive prostate cancer (ie, patients with stage T3 to T4 disease and a PSA &gt;40 ng/mL, Gleason 8 to 10 disease, or else node-positive disease). (See
         <a class="medical medical_review" href="/z/d/html/6951.html" rel="external">
          "Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer", section on 'Patients with low-risk/low-volume disease or not eligible for docetaxel'
         </a>
         .)
        </p>
        <p>
         The following results are available on ADT plus systemic therapy in males with newly diagnosed,
         <strong>
          metastatic
         </strong>
         , castration-sensitive prostate cancer:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Males with newly diagnosed, metastatic, hormone-sensitive prostate cancer receiving
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         in addition to ADT experience significantly improved overall survival [
         <a href="#rid91">
          91,92
         </a>
         ]. In the CHAARTED (Chemohormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) study, these benefits persisted in those over the age of 70 (HR 0.43, 95% CI 0.23-0.78) [
         <a href="#rid91">
          91
         </a>
         ], although the difference was not significant in the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) study (HR 0.90, 95% CI 0.64-1.26) [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similarly, overall survival was improved in those with metastatic hormone-sensitive prostate cancer receiving
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         in addition to ADT [
         <a href="#rid94">
          94,95
         </a>
         ]. Of note, in the LATITUDE (Long-Acting Therapy to Improve Treatment Success in Daily Life) study of abiraterone, approximately 20 percent of males were over the age of 75. In this subset analysis, the effects were attenuated relative to younger males; the difference in overall survival was not statistically significant (HR 0.82, 95% CI 0.53-1.27), whereas radiographic progression-free survival remained statistically significant [
         <a href="#rid94">
          94
         </a>
         ]. Similarly, in the STAMPEDE study of abiraterone, radiographic progression-free survival for males over the age of 70 was improved in those receiving abiraterone in addition to ADT, but the prostate cancer-specific mortality (HR 0.80, 95% CI 0.54-1.17) and overall survival (HR 0.94, 95% CI 0.69-1.29) were not statistically significant [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         A pooled analysis of these three trials specifically examined the benefits of adding
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         or
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         to ADT in males older than 70 years with advanced castration-sensitive prostate cancer [
         <a href="#rid96">
          96
         </a>
         ]. Although progression-free survival was significantly better with the addition of either docetaxel (HR 0.51, 95% CI 0.42-0.61) or abiraterone (HR 0.48, 95% CI 0.36-0.64), overall survival was not improved with either docetaxel (HR 0.86, 95% CI 0.69-1.07) or abiraterone (HR 0.85, 95% CI 0.67-1.08) in males over the age of 70.
        </p>
        <p>
         These studies highlight the potential benefit of these combination therapies in older males while cautioning that uncertainty remains when considering the competing risks of mortality in such patients, reinforcing the importance of a geriatric assessment. Nevertheless, we agree with updated year 2019 consensus-based recommendations from the EAU/ESTRO/SIOG, which suggest ADT plus six cycles of
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         or
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         as a first-line treatment for fit older males with newly diagnosed, high-volume, castration-sensitive, metastatic prostate cancer  (
         <a class="graphic graphic_table graphicRef121951" href="/z/d/graphic/121951.html" rel="external">
          table 12
         </a>
         ) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1505709392">
         <span class="h4">
          ADT plus docetaxel and a second systemic agent
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with metastatic castration-sensitive prostate cancer who are candidates for
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         , decision making about whether to add a second systemic agent to docetaxel plus ADT must be individualized and consider disease extent as well as functional and fitness status.
        </p>
        <p>
         Two trials have demonstrated the superiority of adding a second systemic agent (
         <a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">
          darolutamide
         </a>
         or
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         ) to
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         plus ADT in metastatic castration-sensitive prostate cancer with high-risk/high-volume disease, while a survival benefit from the addition of
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         could not be shown in a third trial. High-risk/high-volume disease in these trials was defined as the presence of visceral metastases and/or ≥4 bone metastases, including at least one outside the vertebral bodies and pelvis, or Gleason score ≥8 disease, or de novo metastatic disease at presentation.
        </p>
        <p>
         This approach could be considered for older males who are sufficiently fit to tolerate combined treatment, as both trials enrolled older males:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Arasens trial (
         <a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">
          darolutamide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         and ADT), the age range included males 75 to 84 (16 percent of enrollees), and males 85 or older represented 0.5 percent of enrollees; they did not do subgroup analysis according to age at enrollment [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the PEACE-1 trial, patients were enrolled up to age 95; however, no subgroup analysis was performed according to age at enrollment [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         These trials are described in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6951.html" rel="external">
          "Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer", section on 'ADT plus docetaxel and a second systemic agent'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H875438812">
         <span class="h4">
          Prostate-directed therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For males with newly diagnosed metastatic prostate cancer, a low burden of bone metastases (defined as four or fewer bone metastases, with none outside the vertebral bodies or pelvis), and no visceral metastases, it is reasonable to pursue prostate RT in conjunction with systemic therapy, rather than systemic therapy alone. The pooled results of two trials (the HORRAD and STAMEDE trials) showed an overall improvement in biochemical progression-free survival (HR 0.74, 95% CI 0.67-0.82) and failure-free survival (HR 0.76, 95% CI 0.69-0.84) that translated into an approximately 10 percent benefit at three years [
         <a href="#rid99">
          99
         </a>
         ]. There was an approximately 7 percent improvement in survival in males with fewer than five bone metastases. There was no evidence that the effect of prostate RT on survival varied in males ≤70 or older than 70 years. (See
         <a class="medical medical_review" href="/z/d/html/6941.html" rel="external">
          "Overview of systemic treatment for recurrent or metastatic castration-sensitive prostate cancer", section on 'Prostate-directed therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H258747729">
         <span class="h3">
          Castration-resistant prostate cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         In both fit and vulnerable patients, the best sequence of treatments for males who progress while receiving ADT (CRPC) is not known. Several options are available, and there are few trials comparing different strategies. An important point is that for most males, ADT should be continued as additional systemic therapy options are utilized sequentially. (See
         <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">
          "Overview of the treatment of castration-resistant prostate cancer (CRPC)", section on 'Continuation of androgen deprivation therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3233408356">
         <span class="h4">
          Non-metastatic castration-resistant prostate cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Three drugs are approved in the United States in this setting, based on studies including patients undergoing ADT who had a PSA doubling time ≤10 months, a PSA value &gt;2 ng/mL, and no evidence of metastatic disease or nodal involvement:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the SPARTAN (Selective Prostate Androgen Receptor Targeting with ARN-509) trial of
         <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">
          apalutamide
         </a>
         (median age 74 years), there was an improvement in metastasis-free survival in males with a PSA doubling time &lt;10 months, including those aged &gt;75 years [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar results were observed with
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         in the PROSPER (Patient-Reported Outcomes following Enzalutamide or Placebo in Men with Non-metastatic, Castration-Resistant Prostate Cancer) trial (median age 74 years) [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar benefits were shown with
         <a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">
          darolutamide
         </a>
         in the ARAMIS (Androgen Receptor Antagonizing Agent for Metastasis-free Survival) trial [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Later analyses of all three trials also confirmed an overall survival benefit compared with placebo [
         <a href="#rid103">
          103-105
         </a>
         ]. In this setting, the efficacies of these three agents have not been compared directly, but they appear to be similar. Differences in the safety profiles may drive the choice of one treatment over another. (See
         <a class="medical medical_review" href="/z/d/html/16351.html" rel="external">
          "Castration-resistant prostate cancer: Treatments targeting the androgen pathway", section on 'Enzalutamide'
         </a>
         .)
        </p>
        <p>
         The metastasis-free survival and overall survival benefits of all three agents in males over age 80 with nonmetastatic CRPC have also been shown in a pooled analysis [
         <a href="#rid106">
          106
         </a>
         ] of patient level data from all three randomized trials [
         <a href="#rid100">
          100-102
         </a>
         ]. However, the analysis also revealed that grade 3 or worse adverse events with androgen signaling inhibitors were reported in a higher percentage of males over age 80 (55 versus 41 percent with placebo) as compared with younger individuals (44 percent versus 30 percent with placebo). The most common of these events were hypertension and bone fracture.
        </p>
        <p class="headingAnchor" id="H3353673782">
         <span class="h4">
          Metastatic castration-resistant prostate cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          Docetaxel
         </a>
         was the first agent that was demonstrated to improve survival in CRPC. More recently, several additional agents (ie,
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         ,
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9916" href="/z/d/drug information/9916.html" rel="external">
          sipuleucel-T
         </a>
         ,
         <a class="drug drug_general" data-topicid="89425" href="/z/d/drug information/89425.html" rel="external">
          radium-223
         </a>
         ,
         <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">
          cabazitaxel
         </a>
         ) have been shown to improve survival and offer additional options for males with castration-resistant disease. Several of the pivotal studies using these newer agents included a significant proportion of older males, with similar improved survival compared with younger males. (See
         <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">
          "Overview of the treatment of castration-resistant prostate cancer (CRPC)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Androgen pathway interference
         </strong>
         – Both
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         and
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         have demonstrated improved survival in chemotherapy-naïve males with asymptomatic or minimally symptomatic disease [
         <a href="#rid107">
          107,108
         </a>
         ], as well as in those who had previously received
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         [
         <a href="#rid109">
          109,110
         </a>
         ]. The effects were similar in subset analyses of males over the age of 75. (See
         <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">
          "Overview of the treatment of castration-resistant prostate cancer (CRPC)", section on 'Interference with androgenic stimulation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16351.html" rel="external">
          "Castration-resistant prostate cancer: Treatments targeting the androgen pathway"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For frail patients or those who are not candidates for
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         , use of
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         or
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         is an option. Even in the post-docetaxel setting, the response rates for abiraterone and enzalutamide have been similar in older and younger males, with similar overall adverse events, although specific complications were higher in older males in the abiraterone (atrial fibrillation and tachycardia) and enzalutamide (peripheral edema, fatigue, and diarrhea) studies [
         <a href="#rid111">
          111,112
         </a>
         ]. Of note, 85 percent of the males in these studies had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chemotherapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Healthy/fit males
         </strong>
         – Healthy males should be offered standard chemotherapy. However, in an analysis of SEER-Medicare data through 2004, the majority of older males with metastatic prostate cancer did not receive chemotherapy [
         <a href="#rid113">
          113
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6945.html" rel="external">
          "Chemotherapy in advanced castration-resistant prostate cancer", section on 'Chemotherapy-naïve patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vulnerable males
         </strong>
         – Vulnerable males may be able to receive standard chemotherapy after correction/treatment of a specific reversible impairment if one is identified [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Docetaxel
         </strong>
         – The standard chemotherapy regimen for CRPC is
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         (75 mg/m
         <sup>
          2
         </sup>
         every three weeks) with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         . Subset analyses of the trials establishing the role of this approach have shown that older males, including those ≥75 years, responded as well as younger patients [
         <a href="#rid114">
          114,115
         </a>
         ]. However, the challenges of using docetaxel in older individuals are well recognized [
         <a href="#rid116">
          116
         </a>
         ]. In one study, treatment with docetaxel plus prednisone was not feasible in males aged 75 and older who were considered vulnerable or frail [
         <a href="#rid117">
          117
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Because of concerns about myelosuppression and other adverse effects of chemotherapy in older patients [
         <a href="#rid118">
          118
         </a>
         ], studies have explored lower dosing of
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         (30 mg/m
         <sup>
          2
         </sup>
         weekly) [
         <a href="#rid116">
          116,119-121
         </a>
         ]. Results have suggested that this dosing may be effective against cancer progression, with a lower rate of myelosuppression, although with no improvement in overall survival. However, a review of patients treated with either three-week (n = 96) or weekly (n = 80) docetaxel found that there was a greater percentage of dropouts with the weekly regimen compared with the three-week schedule (30 versus 8 percent) [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         If
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         is used in older males, we typically start with a lower dose (60 or 65 mg/m
         <sup>
          2
         </sup>
         ) every three weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Cabazitaxel
         </strong>
         –
         <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">
          Cabazitaxel
         </a>
         is a taxane derivative that has been shown to prolong survival compared with
         <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">
          mitoxantrone
         </a>
         in patients who have progressed on
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         [
         <a href="#rid122">
          122,123
         </a>
         ]. The improvement in survival was not affected by age. The CARD trial also showed improved outcomes with cabazitaxel versus
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         /
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         in males progressing after prior docetaxel and the alternative agent (abiraterone or enzalutamide); benefits were similar in older males although with more treatment-emergent adverse effects compared with abiraterone/enzalutamide [
         <a href="#rid124">
          124
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6945.html" rel="external">
          "Chemotherapy in advanced castration-resistant prostate cancer", section on 'Men who have received prior docetaxel'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">
          Cabazitaxel
         </a>
         is associated with less neuropathy than
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         , and it is the preferred taxane for older males with preexisting neuropathy who are docetaxel-naïve. There are at least two studies of modified schedules of cabazitaxel that might be associated with a more favorable toxicity profile in older males [
         <a href="#rid125">
          125,126
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Frail males
         </strong>
         – The role of chemotherapy in frail males (ie, those with an irreversible impairment) is less certain; an adapted treatment regimen may be considered. Chemotherapy is generally not indicated in males with terminal illness, and treatment is symptomatic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radium-223
         </strong>
         – Another therapeutic option for males without visceral metastases is
         <a class="drug drug_general" data-topicid="89425" href="/z/d/drug information/89425.html" rel="external">
          radium-223
         </a>
         , which has been shown to decrease the incidence of skeletal-related events and prolong overall survival in males with widely disseminated bone metastases [
         <a href="#rid6">
          6,127
         </a>
         ]. In the phase III trial demonstrating the safety and efficacy of this agent, the median age of the patients was 71 years. (See
         <a class="medical medical_review" href="/z/d/html/17128.html" rel="external">
          "Bone metastases in advanced prostate cancer: Management", section on 'Radium-223'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunotherapy
         </strong>
         –
         <a class="drug drug_general" data-topicid="9916" href="/z/d/drug information/9916.html" rel="external">
          Sipuleucel-T
         </a>
         , a dendritic cell vaccine that is prepared from peripheral blood mononuclear cells obtained by leukapheresis, has been shown to prolong overall survival in males with minimally symptomatic, metastatic CRPC. There was no difference in the effects in older versus younger patients [
         <a href="#rid128">
          128
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6937.html" rel="external">
          "Immunotherapy for castration-resistant prostate cancer", section on 'Therapeutic vaccination with Sipuleucel-T'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In May 2017, the US Food and Drug Administration (FDA) approved the immune checkpoint inhibitor
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         for treatment of a variety of advanced solid tumors (including prostate adenocarcinoma) that have high levels of microsatellite instability (MSI-H) or are deficient in mismatch repair (dMMR), that progressed following prior treatment, and for which there are no satisfactory alternative treatment options. (See
         <a class="medical medical_review" href="/z/d/html/6937.html" rel="external">
          "Immunotherapy for castration-resistant prostate cancer", section on 'PD-1 pathway inhibition'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4113123">
         <span class="h3">
          Surveillance during treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surveillance strategies during treatment for advanced prostate cancer are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">
          "Overview of the treatment of castration-resistant prostate cancer (CRPC)", section on 'Assessment during treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2678923771">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117831.html" rel="external">
          "Society guideline links: Diagnosis and management of prostate cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H258749561">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The management of prostate cancer in older males requires careful assessment of multiple factors, including comorbidities, dependency, activities of daily living, and nutritional status, which ultimately are more important than chronologic age. Based on a detailed assessment of these parameters  (
         <a class="graphic graphic_table graphicRef121919" href="/z/d/graphic/121919.html" rel="external">
          table 1
         </a>
         ), patients should be categorized as fit, vulnerable, or frail  (
         <a class="graphic graphic_algorithm graphicRef121917" href="/z/d/graphic/121917.html" rel="external">
          algorithm 1
         </a>
         ). Vulnerable or frail patients should undergo a comprehensive geriatric assessment. (See
         <a class="local">
          'Patient classification based on health status'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2808.html" rel="external">
          "Comprehensive geriatric assessment for patients with cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For males with localized prostate cancer, the choice of treatment depends on the assessment of the patient's overall status, his estimated life expectancy, as well as the risk stratification of his primary tumor  (
         <a class="graphic graphic_table graphicRef121918" href="/z/d/graphic/121918.html" rel="external">
          table 11
         </a>
         ). (See
         <a class="local">
          'Localized disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Healthy older males should have the same range of potentially curative treatment options as younger patients, including radical prostatectomy and radiation therapy (RT; external beam and/or brachytherapy); active surveillance is an appropriate option for many patients with very low- and low-risk disease and for some males with favorable intermediate-risk disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vulnerable patients with a reversible problem who have high-risk localized prostate cancer generally should receive the same definitive treatment as younger patients, following appropriate management of their other underlying problems. For individuals with low-/intermediate-risk localized prostate cancer, active surveillance or watchful waiting is generally preferred.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Frail older males with an irreversible problem should generally receive symptomatic/palliative management without definitive treatment (eg, initial hormone therapy).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early referral to palliative care is encouraged for older males with prostate cancer, particularly in the setting of advanced castration-resistant disease. (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with advanced prostate cancer are managed initially with androgen deprivation therapy (ADT). Particular attention should be paid to the complications of ADT and the potential interactions with underlying comorbidities  (
         <a class="graphic graphic_table graphicRef121951" href="/z/d/graphic/121951.html" rel="external">
          table 12
         </a>
         ). (See
         <a class="local">
          'Castration-sensitive prostate cancer'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6951.html" rel="external">
          "Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6927.html" rel="external">
          "Side effects of androgen deprivation therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The addition of
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         or
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         to ADT is a reasonable first-line treatment for fit older males with newly diagnosed, high-volume, castration-sensitive, metastatic disease. Given the uncertainty of benefit when considering the competing risks of mortality in such patients, a geriatric assessment should be undertaken in these individuals. (See
         <a class="local">
          'ADT plus systemic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals who are candidates for
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         , decision making about whether to add a second systemic agent to docetaxel plus ADT must be individualized and consider disease extent as well as functional and fitness status. (See
         <a class="local">
          'ADT plus docetaxel and a second systemic agent'
         </a>
         above.).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For males with newly diagnosed metastatic disease, a low burden of bone metastases (defined as four or fewer bone metastases, with none outside the vertebral bodies or pelvis), and no visceral metastases, it is reasonable to pursue prostate RT in conjunction with systemic therapy, rather than systemic therapy alone. (See
         <a class="local">
          'Prostate-directed therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Males with a rising prostate-specific antigen (PSA) after ADT who have a PSA doubling time ≤10 months, a PSA value &gt;2 ng/mL, and no evidence of metastatic disease or nodal involvement are appropriate candidates for
         <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">
          apalutamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         , or
         <a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">
          darolutamide
         </a>
         . (See
         <a class="local">
          'Non-metastatic castration-resistant prostate cancer'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Males with metastatic castration-resistant prostate cancer can be candidates for the same therapies as younger patients, including chemotherapy (
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         ,
         <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">
          cabazitaxel
         </a>
         ),
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         ,
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">
          apalutamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="89425" href="/z/d/drug information/89425.html" rel="external">
          radium-223
         </a>
         , and
         <a class="drug drug_general" data-topicid="9916" href="/z/d/drug information/9916.html" rel="external">
          sipuleucel-T
         </a>
         . The choice and sequence of therapy should incorporate information about the overall clinical status of the patient. Abiraterone and enzalutamide are appropriate options for older males who are not candidates for chemotherapy. (See
         <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">
          "Overview of the treatment of castration-resistant prostate cancer (CRPC)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1891758842">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         We are saddened by the death of Nicholas Vogelzang, MD, who passed away in September 2022. UpToDate gratefully acknowledges Dr. Vogelzang's role as Section Editor on this topic, and his dedicated and longstanding involvement with the UpToDate program.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          SEER Cancer Statistics Review, 1975-2006, Horner MJ, Ries LAG, Krapcho M, et al (Eds), National Cancer Institute, Bethesda. Based on November 2008 SEER data submission, posted to the SEER web site 2009. https://seer.cancer.gov/csr/1975_2006/ (Accessed on July 26, 2019).
         </li>
         <li class="breakAll">
          National Cancer Institute. SEER Cancer Stat Facts: Prostate cancer. https://seer.cancer.gov/statfacts/html/prost.html (Accessed on July 24, 2019).
         </li>
         <li class="breakAll">
          SEER Cancer Statistics Review, 1975-2006, Ries LAG, Melbert D, Krapcho M, et al (Eds), National Cancer Institute, Bethesda. Based on December 2009 SEER data submission, posted to the SEER web site 2008. http://seer.cancer.gov/csr/1975-2005/ (Accessed on July 26, 2019).
         </li>
         <li class="breakAll">
          International Agency for Research on Cancer (IARC). Globocan 2018. Estimated cancer incidence, mortality, and prevalence worldwide in 2018. Online analysis: Cancer tomorrow. http://gco.iarc.fr/ (Accessed on July 24, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pal SK, Katheria V, Hurria A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin 2010; 60:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Droz JP, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014; 15:e404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Droz JP, Albrand G, Gillessen S, et al. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. Eur Urol 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyle HJ, Alibhai S, Decoster L, et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer 2019; 116:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellera CA, Rainfray M, Mathoulin-Pélissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 2012; 23:2166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borson S, Scanlan J, Brush M, et al. The mini-cog: a cognitive 'vital signs' measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry 2000; 15:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol 2018; 36:2326.
          </a>
         </li>
         <li class="breakAll">
          NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed on July 24, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Droz JP, Balducci L, Bolla M, et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol 2010; 73:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohile SG, Dale W, Somerfield MR, Hurria A. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology Summary. J Oncol Pract 2018; 14:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeldres C, Latouff JB, Saad F. Predicting life expectancy in prostate cancer patients. Curr Opin Support Palliat Care 2009; 3:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walz J, Gallina A, Perrotte P, et al. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int 2007; 100:1254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walz J, Suardi N, Shariat SF, et al. Accuracy of life tables in predicting overall survival in patients after radical prostatectomy. BJU Int 2008; 102:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walz J, Gallina A, Saad F, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007; 25:3576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang DD, Mahal BA, Muralidhar V, et al. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. Cancer 2017; 123:4832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skolarus TA, Caram ME, Chapman CH, et al. Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de-implementation. Cancer 2018; 124:3971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houterman S, Janssen-Heijnen ML, Verheij CD, et al. Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study. Prostate Cancer Prostatic Dis 2006; 9:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konety BR, Cowan JE, Carroll PR, CaPSURE Investigators. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol 2008; 179:1797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bubolz T, Wasson JH, Lu-Yao G, Barry MJ. Treatments for prostate cancer in older men: 1984-1997. Urology 2001; 58:977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA 2015; 314:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sammon JD, Abdollah F, Reznor G, et al. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. Eur Urol 2015; 68:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu-Yao GL, Albertsen PC, Moore DF, et al. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer. JAMA Intern Med 2014; 174:1460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Potosky AL, Haque R, Cassidy-Bushrow AE, et al. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol 2014; 32:1324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu-Yao GL, Albertsen PC, Moore DF, et al. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer. Eur Urol 2015; 68:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daskivich TJ, Fan KH, Koyama T, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med 2013; 158:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014; 370:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bill-Axelson A, Holmberg L, Garmo H, et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med 2018; 379:2319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006; 296:2683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun L, Caire AA, Robertson CN, et al. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol 2009; 182:2242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magheli A, Rais-Bahrami S, Humphreys EB, et al. Impact of patient age on biochemical recurrence rates following radical prostatectomy. J Urol 2007; 178:1933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siddiqui SA, Sengupta S, Slezak JM, et al. Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J Urol 2006; 175:952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malaeb BS, Rashid HH, Lotan Y, et al. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts. Urol Oncol 2007; 25:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierorazio PM, Humphreys E, Walsh PC, et al. Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians. BJU Int 2010; 106:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeldres C, Suardi N, Walz J, et al. Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. Eur Urol 2008; 54:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tewari A, Johnson CC, Divine G, et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004; 171:1513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kundu SD, Roehl KA, Eggener SE, et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004; 172:2227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman RM, Barry MJ, Stanford JL, et al. Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study. Am J Med 2006; 119:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohamad BA, Marszalek M, Brössner C, et al. Radical prostatectomy in Austria: a nationwide analysis of 16,524 cases. Eur Urol 2007; 51:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu JC, Elkin EP, Pasta DJ, et al. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol 2004; 171:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shikanov S, Desai V, Razmaria A, et al. Robotic radical prostatectomy for elderly patients: probability of achieving continence and potency 1 year after surgery. J Urol 2010; 183:1803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greco KA, Meeks JJ, Wu S, Nadler RB. Robot-assisted radical prostatectomy in men aged &gt; or =70 years. BJU Int 2009; 104:1492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilbert SM, Kuo YF, Shahinian VB. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol 2011; 29:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Amico AV, Cote K, Loffredo M, et al. Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma. Cancer 2003; 97:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dosoretz AM, Chen MH, Salenius SA, et al. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy. Cancer 2010; 116:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jani AB, Gratzle J. Analysis of impact of age and race on biochemical control after radiotherapy in different prostate cancer settings. Urology 2005; 66:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnstone PA, Riffenburgh RH, Moul JW, et al. Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research. Int J Radiat Oncol Biol Phys 2003; 55:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Amico AV, Chen MH, Renshaw A, et al. Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA 2015; 314:1291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giacalone NJ, Wu J, Chen MH, et al. Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial. J Clin Oncol 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nanda A, Chen MH, Moran BJ, et al. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy. Int J Radiat Oncol Biol Phys 2010; 77:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman KE, Chen MH, Moran BJ, et al. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. Cancer 2010; 116:2590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009; 302:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378:2104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fosså SD, Wiklund F, Klepp O, et al. Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7. Eur Urol 2016; 70:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bekelman JE, Mitra N, Handorf EA, et al. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer. J Clin Oncol 2015; 33:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jani AB, Parikh SD, Vijayakumar S, Gratzle J. Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer. Urology 2005; 65:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geinitz H, Zimmermann FB, Thamm R, et al. 3D conformal radiation therapy for prostate cancer in elderly patients. Radiother Oncol 2005; 76:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villa S, Bedini N, Fallai C, Olmi P. External beam radiotherapy in elderly patients with clinically localized prostate adenocarcinoma: age is not a problem. Crit Rev Oncol Hematol 2003; 48:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu L, Glicksman AS, Coachman N, Kuten A. Low acute gastrointestinal and genitourinary toxicities in whole pelvic irradiation of prostate cancer. Int J Radiat Oncol Biol Phys 1997; 38:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schultheiss TE, Hanks GE, Hunt MA, Lee WR. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate. Int J Radiat Oncol Biol Phys 1995; 32:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skwarchuk MW, Jackson A, Zelefsky MJ, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 2000; 47:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen AB, D'Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 2006; 24:5298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinkawa M, Fischedick K, Gagel B, et al. Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment. BMC Cancer 2009; 9:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol 2022; 208:10.
          </a>
         </li>
         <li class="breakAll">
          NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed on May 01, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrell BR, Temel JS, Temin S, Smith TJ. Integration of Palliative Care Into Standard Oncology Care: ASCO Clinical Practice Guideline Update Summary. J Oncol Pract 2017; 13:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001; 86:2787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakhireva LN, Barrett-Connor E, Kritz-Silverstein D, Morton DJ. Modifiable predictors of bone loss in older men: a prospective study. Am J Prev Med 2004; 26:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR, Saad F, Egerdie B, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol 2012; 30:3271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basaria S, Muller DC, Carducci MA, et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24:3979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harle LK, Maggio M, Shahani S, et al. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol 2006; 4:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy 2008; 28:1511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leahy Y. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy. Clin J Oncol Nurs 2008; 12:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28:1769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med 2006; 166:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayadevappa R, Chhatre S, Malkowicz SB, et al. Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer. JAMA Netw Open 2019; 2:e196562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25:1596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368:1314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 2018; 36:1080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James ND, Sydes MR, Mason MD, et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 2012; 13:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2017; 377:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James ND, de Bono JS, Spears MR, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017; 377:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landre T, Guetz GD, Chouahnia K, et al. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis. Clin Genitourin Cancer 2019; 17:e806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 2022; 386:1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 2022; 399:1695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burdett S, Boevé LM, Ingleby FC, et al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol 2019; 76:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med 2018; 378:1408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hussain M, Fizazi K, Saad F, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2018; 378:2465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fizazi K, Shore N, Tammela TL, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2019; 380:1235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med 2020; 383:1040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR, Saad F, Chowdhury S, et al. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol 2021; 79:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2020; 382:2197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fallah J, Zhang L, Amatya A, et al. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. Lancet Oncol 2021; 22:1230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulders PF, Molina A, Marberger M, et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur Urol 2014; 65:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sternberg CN, de Bono JS, Chi KN, et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol 2014; 25:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onukwugha E, Mullins CD, Hsu VD, et al. Effect of urologists and medical oncologists on treatment of elderly men with Stage IV prostate cancer. Urology 2011; 77:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson J, Van Poppel H, Bellmunt J, et al. Chemotherapy for older patients with prostate cancer. BJU Int 2007; 99:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Italiano A, Ortholan C, Oudard S, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009; 55:1368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mourey L, Gravis G, Sevin E, et al. Feasibility of docetaxel-prednisone (DP) in frail elderly (age 75 and older) patients with castration-resistant metastatic prostate cancer (CRMPC): GERICO10-GETUG P03 trial led by Unicancer. J Clin Oncol 2014; 34S: ASCO #152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdel-Rahman O. Efficacy and toxicity outcomes of elderly castrate-resistant prostate cancer patients treated with docetaxel-A pooled analysis of 3 randomized studies. Urol Oncol 2020; 38:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beer TM, Berry W, Wersinger EM, Bland LB. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin Prostate Cancer 2003; 2:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fosså SD. A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer. Front Radiat Ther Oncol 2008; 41:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hervonen P, Joensuu H, Joensuu T, et al. Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer. Anticancer Res 2012; 32:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 2013; 24:2402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sternberg CN, Castellano D, de Bono J, et al. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. Eur Urol 2021; 80:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Climent MÁ, Pérez-Valderrama B, Mellado B, et al. Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial. Eur J Cancer 2017; 87:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clément-Zhao A, Auvray M, Aboudagga H, et al. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer. BJU Int 2018; 121:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14257 Version 51.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://seer.cancer.gov/csr/1975_2006/" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : SEER Cancer Statistics Review, 1975-2006, Horner MJ, Ries LAG, Krapcho M, et al (Eds), National Cancer Institute, Bethesda. Based on November 2008 SEER data submission, posted to the SEER web site 2009. https://seer.cancer.gov/csr/1975_2006/ (Accessed on July 26, 2019).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://seer.cancer.gov/statfacts/html/prost.html" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : National Cancer Institute. SEER Cancer Stat Facts: Prostate cancer. https://seer.cancer.gov/statfacts/html/prost.html (Accessed on July 24, 2019).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="http://seer.cancer.gov/csr/1975-2005/" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : SEER Cancer Statistics Review, 1975-2006, Ries LAG, Melbert D, Krapcho M, et al (Eds), National Cancer Institute, Bethesda. Based on December 2009 SEER data submission, posted to the SEER web site 2008. http://seer.cancer.gov/csr/1975-2005/ (Accessed on July 26, 2019).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="http://gco.iarc.fr/" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : International Agency for Research on Cancer (IARC). Globocan 2018. Estimated cancer incidence, mortality, and prevalence worldwide in 2018. Online analysis: Cancer tomorrow. http://gco.iarc.fr/ (Accessed on July 24, 2019).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20173172" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Evaluating the older patient with cancer: understanding frailty and the geriatric assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25079103" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28089304" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31195356" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22250183" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Screening older cancer patients: first evaluation of the G-8 geriatric screening tool.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11113982" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The mini-cog: a cognitive 'vital signs' measure for dementia screening in multi-lingual elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29782209" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29782209" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19836968" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29932846" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology Summary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19553817" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Predicting life expectancy in prostate cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17979925" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18384631" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Accuracy of life tables in predicting overall survival in patients after radical prostatectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17704404" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9749478" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28832984" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30192374" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de-implementation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16534509" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18343440" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11744472" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Treatments for prostate cancer in older men: 1984-1997.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26151271" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Trends in Management for Patients With Localized Prostate Cancer, 1990-2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25457017" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25023796" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24638009" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25800944" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23689764" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24597866" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Radical prostatectomy or watchful waiting in early prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30575473" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17164454" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Survival associated with treatment vs observation of localized prostate cancer in elderly men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19758616" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17868723" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Impact of patient age on biochemical recurrence rates following radical prostatectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16469591" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17628294" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20201836" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17996358" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15017210" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15538237" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10647798" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16651054" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16835007" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Radical prostatectomy in Austria: a nationwide analysis of 16,524 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14713791" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Predicting quality of life after radical prostatectomy: results from CaPSURE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20299041" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Robotic radical prostatectomy for elderly patients: probability of achieving continence and potency 1 year after surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19583731" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Robot-assisted radical prostatectomy in men aged&gt;or =70 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20124165" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Time trends and local variation in primary treatment of localized prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19926311" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12491505" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20052734" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15992908" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Analysis of impact of age and race on biochemical control after radiotherapy in different prostate cancer settings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12605974" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18212313" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26393854" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27601545" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19744800" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20310055" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19706860" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19091394" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22056152" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27025586" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25559808" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15913725" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15990188" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : 3D conformal radiation therapy for prostate cancer in elderly patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14607384" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : External beam radiotherapy in elderly patients with clinically localized prostate adenocarcinoma: age is not a problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9212006" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Low acute gastrointestinal and genitourinary toxicities in whole pelvic irradiation of prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7790250" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10758311" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17114664" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Patient and treatment factors associated with complications after prostate brachytherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19703300" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35536144" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35536144" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28972832" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Integration of Palliative Care Into Standard Oncology Care: ASCO Clinical Practice Guideline Update Summary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15647578" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Risk of fracture after androgen deprivation for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11397888" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15165661" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Modifiable predictors of bone loss in older men: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22649143" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Sarcopenia during androgen-deprivation therapy for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16388523" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16921050" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17099626" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19025432" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18842533" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11790215" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15983333" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17000207" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Metabolic syndrome and risk of cardiovascular disease: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16505268" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31268539" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17404365" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23550669" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Intermittent versus continuous androgen deprivation in prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29384722" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26719232" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22452894" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28578607" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28578639" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31227430" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35179323" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35405085" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30826218" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29420164" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29949494" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30763142" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32905676" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32907777" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Apalutamide and Overall Survival in Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32469184" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34310904" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24881730" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Enzalutamide in metastatic prostate cancer before chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23228172" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Abiraterone in metastatic prostate cancer without previous chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21612468" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Abiraterone and increased survival in metastatic prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22894553" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Increased survival with enzalutamide in prostate cancer after chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24099659" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24478320" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21439617" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Effect of urologists and medical oncologists on treatment of elderly men with Stage IV prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18182665" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16981902" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Chemotherapy for older patients with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18706755" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Feasibility of docetaxel-prednisone (DP) in frail elderly (age 75 and older) patients with castration-resistant metastatic prostate cancer (CRMPC): GERICO10-GETUG P03 trial led by Unicancer
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31585778" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Efficacy and toxicity outcomes of elderly castrate-resistant prostate cancer patients treated with docetaxel-A pooled analysis of 3 randomized studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15040860" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18544992" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22399616" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20888992" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23723295" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34274136" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29102858" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28370882" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23863050" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Alpha emitter radium-223 and survival in metastatic prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20818862" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
